Journal of Antimicrobial Chemotherapy (2000) 45, 623-631
© 2000 The British Society for Antimicrobial Chemotherapy
Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis
a Departments of Pediatrics, b Microbiology and Immunology, Baylor College of Medicine, c Infectious Disease Laboratory, Texas Children's Hospital, Houston, TX 77030; d Bristol–Myers Squibb, Plainsboro, NJ 08536, USA
Ninety-two laboratories in the USA submitted isolates of Streptococcus pneumoniae to a single laboratory for susceptibility testing. Overall, 64% of 4489 isolates were susceptible to penicillin, 24% were intermediate and 13% were resistant to penicillin, although susceptibilities varied depending on geographical region. Macrolide/azalide resistance varied from 4 to 30%, with some regions having macrolide/azalide resistance higher than penicillin resistance. Children 12 years of age were significantly more likely to be infected with a penicillin-resistant pneumococcus than were adolescents or adults. Isolates from the respiratory tract were more likely to be penicillin resistant and >50% of pneumococci from the ear were resistant to penicillin. Almost 25% of penicillin-susceptible isolates had cefaclor MICs 2.0 mg/L and 15% of penicillin-susceptible isolates had loracarbef MICs 2.0 mg/L. These isolates would be erroneously reported as susceptible using NCCLS guidelines, and this finding may explain the lack of clinical response in patients treated with these antibiotics. The predicted plasma concentrations of all cephalosporins tested exceeded the geometric mean MIC for at least 40% of the dosing interval for penicillin-susceptible S. pneumoniae; for penicillin-intermediate S. pneumoniae, only cefprozil (56%), cefuroxime (64%) and cefpodoxime (63%) reached >40% of time above the geometric mean MIC in the dosing interval. None of the cephalosporins evaluated achieved a substantial time above the geometric mean MIC during its dosing interval for fully penicillin-resistant S. pneumoniae.
* Correspondence address. Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Tel: +1-713-770-4330; Fax: +1-713-770-4347; E-mail: emason{at}bcm.tmc.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Smith, L. M. Ednie, P. C. Appelbaum, S. Hawser, and S. Lociuro Antistreptococcal Activity of AR-709 Compared to That of Other Agents Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2279 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Matic, K. Kosowska, B. Bozdogan, L. M. Kelly, K. Smith, L. M. Ednie, G. Lin, K. L. Credito, C. L. Clark, P. McGhee, et al. Antipneumococcal Activities of Two Novel Macrolides, GW 773546 and GW 708408, Compared with Those of Erythromycin, Azithromycin, Clarithromycin, Clindamycin, and Telithromycin Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4103 - 4112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Jacobs, D. Felmingham, P. C. Appelbaum, R. N. Gruneberg, and the Alexander Project Group The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J. Antimicrob. Chemother., August 1, 2003; 52(2): 229 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bingen, C. Doit, C. Loukil, N. Brahimi, P. Bidet, D. Deforche, and P. Geslin Activity of Telithromycin against Penicillin-Resistant Streptococcus pneumoniae Isolates Recovered from French Children with Invasive and Noninvasive Infections Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2345 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Preston, M. R. Turnak, M. R. Jacobs, P. C. Appelbaum, G. G. Zhanel, D. E. Low, and W. Craig Assumed versus Approved Breakpoints Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3243 - 3245. [Full Text]
|
|